| Name | Verdiperstat |
| Description | Verdiperstat (AZD 3241) is a selective, irreversible and orally active myeloperoxidase inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders. |
| In vitro | Verdiperstat (AZD3241) functions as a myeloperoxidase (MPO) inhibitor, demonstrating potency with an IC50 value of 630 nM. It is primarily utilized in the study of neurodegenerative brain disorders[1]. By selectively and irreversibly targeting MPO, Verdiperstat (AZD3241) potentially reduces oxidative stress, consequently diminishing prolonged neuroinflammation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (39.48 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 250 mg/mL (986.89 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (39.48 mM), Solution.
|
| Keywords | Verdiperstat | myeloperoxidase | Inhibitor | inhibit | GlutathionePeroxidase | Glutathione Peroxidase | AZD-3241 |
| Inhibitors Related | AZD8309 | ML-210 | (±)-Methyl Jasmonate | 4-Aminosalicylic acid | 2-Acetamidophenol | PF-1355 | Sodium 2-mercaptoethanesulfonate | 5-Aminosalicylic Acid | Melatonin | 4-Methylesculetin | Probucol | Cefdinir |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Glutamine Metabolism Compound Library | Antioxidant Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Oxidation-Reduction Compound Library |